港股异动|中国新华教育涨逾4%获投行及券商看好
格隆汇7月19日丨中国新华教育(2779.HK)现涨4.32%,报2.9港元,暂成交431万,最新总市值47港元。
国金证券指,公司7月12日拟收购富达公司持有的昆明医科大学海源学院及昆明市卫生学校60%举办者权益彰显信心。本次收购是公司业务首次延伸到长三角区域以外,有助于学校网络扩张及渗透率提升。预计公司FY19、20年归母净利润2.82/3.34亿元,维持买入评级,目标价4港元。
而麦格理认为,此次收购可由今年9月开始提升集团的收入及盈利,上调公司今年至2021年的纯利预测分别11%、18%及15%,以现金流贴现率计,目标价相应由3.7港元升至4.2港元,评级维持“跑赢大市”。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.